Johnson & Johnson (NYSE:JNJ) is one of the 15 Best Stocks to Buy According to Billionaire Ray Dalio.
Johnson & Johnson (NYSE:JNJ) has featured in the 13F portfolio of Bridgewater Associates for more than a decade and a half. The fund has held a small position in the company since early 2011, growing this stake to 4.71 million shares at its peak in the second quarter of 2022. Since then, it has trimmed this holding. Filings for the fourth quarter of 2025 show that the fund owned 1.31 million shares in the pharmaceutical, biotechnology, and medical technologies corporation. This stake represents a decrease of 23% compared to filings for the previous quarter. The stock is among the top fifteen biggest positions of Dalio, per the 13F portfolio.
READ NEXT: 33 Stocks That Should Double in 3 Years.
Johnson & Johnson (NYSE:JNJ) is favored by institutional investors because it has an impressive dividend history stretching back more than six decades. The company has a history of dividend growth that has lasted for sixty-three years, and counting. Since the 2023 spinoff of the consumer health business by Johnson & Johnson, hedge funds view the company as a higher-margin, faster-growing company. By focusing solely on Innovative Medicine and MedTech, JNJ has accelerated its revenue growth. In early 2026, the company forecast sales of $100 billion, exceeding Wall Street estimates. Funds are particularly bullish on the blockbuster cancer drug Darzalex, which surpassed expectations in Q4 2025, and the new therapy Carvykti, which hit $1 billion in annual sales for the first time.
While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News
